Prostate cancer: where we have been, where we are, where we are going.
Prostate cancer has generated more debate over the last decade than perhaps any other malignancy. This stems from many factors, not the least of which is the fact that the histologic incidence far exceeds clinically manifested disease. Despite this fact, prostate cancer remains the most common male malignancy and the second most common cause of cancer-related mortality in most Western societies. Significant advances have occurred in virtually all domains surrounding prostate cancer, including increased understanding of the molecular and genetic basis of the disease, improved methods of early detection and screening, refinement of biopsy techniques, and advances in staging and therapeutic approaches. Even with these advances, the sobering mortality statistics clearly underscore the need for further insight and progress.
Brawer
M K
MK
Northwest Prostate Institute, Pacific Northwest Cancer Foundation, Seattle, Washington 98133, USA. mbrawer@nwhsea.org
D015415:Biomarkers / Q000097:blood; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis
D015415:Biomarkers; D017430:Prostate-Specific Antigen